AloeVeritas Announces Preliminary Data from Ongoing Phase 1 Observational

Study of AloeMD

AloeVeritas Announces Preliminary Data from Ongoing Phase 1 Observational Study of AloeMD (a
drug-less pain disruptor) Showing Strong Evidence of Significant Results in Participants with Acute
and Chronic Pain

Dallas, TX, May 24, 2018 --(PR.com)-- AloeVeritas, a leader in discovering, developing and advancing
natural botanical compounds with the potential to address the unmet need that exists for consumers
experiencing chronic pain with little to no long-term relief from common pain modalities, today
announced preliminary data from its ongoing Phase 1 Observational Study of AloeMD. AloeMD is a
drug-free analgesic containing a patented 100% natural pain disruptor and reliever formulated in an
orthomolecular compound, which targets the extra cellular matrix through a novel mechanism of topical
smart absorption delivery technology, allowing the body to ultimately repair itself, naturally, without the
use of opioids or toxic chemicals.

The new data from the initial dose and application portion of the Phase 1 study showed strong
observational activity regardless of demographic variations, prior treatment with prescription medications
or the presence of acute or chronic pain maladies.

As of the date May 21, 2018, a remarkable pain control rate of 87 percent was found in participants
evaluable for response, based on the Global Professional Observational Organizations's (GPOSO)
consensus criteria. The overall response rate is currently 72%. As of the data cutoff date, AloeMD was
well-tolerated with no adverse events reported during the study period. In addition, there were no
discontinuations due to treatment-related adverse events, and 89 percent of participants remained on
treatment with an overall satisfaction rate of 83 percent. The data is presented in real-time calculations on
the AloeVeritas' PainSmarts official webpage @ www.painsmarts.org.

Based on these data, AloeVeritas plans to continue to engage global studies in the second half of 2018. In
addition, AloeVeritas continues to enroll participants in the expansion portion of the ongoing Phase 1
observational study in participants with acute to chronic pain with the goal of generating additional data
in 2018.

"The new observational study results for AloeMD represent an exciting milestone for the drugless pain
relief community. The data showed a remarkably high response rate and a favorable tolerability profile,
suggesting AloeMD has the potential to transform the future of pain relief by utilizing natural ingredients
that may help to eliminate the overuse of Opioids, Steroids or NSAIDS in the majority of the population,"
said Christopher Hardy, CEO of AloeVeritas. "The data also provides strong evidence that targeting
inflammation and extracellular matrix instability - a pain-driver present in nearly all participants across
the spectrum of the study - is a potentially important treatment strategy that may offer consumers
improved outcomes with continued use. These data strongly support continued development of
AloeVeritas' unique aloe-based ingredients in multiple product offerings across a broad population of
participants with multiple chronic conditions.”

Page 1/3
PR.com Press Release Distribution Terms of Use
For more information on AloeVeritas and PainSmarts, please visit the company's web site at
www.aloeveritas.com or to volunteer as a study participant visit www.painsmarts.org or call
1-833-Tru-Aloe to speak to a customer care representative.

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
AloeVeritas Americas, LLC
Jillian Corley
833-TRU-ALOE
Contact via Email
www.aloeveritas.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/754678

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use